[ALS Association](https://www.als.org)

September 23, 2025 (LOI) | January 13, 2026 (Full application)

Maximum direct costs: $5 million per project; project duration up to 5 years.

Supports patient-centered comparative clinical effectiveness research (CER) on rare diseases, emphasizing stakeholder and patient engagement.

--- ## Description This funding opportunity supports high-quality, patient-centered comparative clinical effectiveness research (CER) projects focused on rare diseases. The program aims to address the unique challenges faced by patients with rare diseases by fostering innovative research that is responsive to patient and stakeholder needs. Applicants are expected to incorporate comprehensive engagement strategies with patients and stakeholders throughout the research process. The initiative encourages collaboration among health researchers, scientists, healthcare professionals, research directors, and academic institutions to generate meaningful evidence for rare disease care and decision-making. --- ## Due Dates - September 23, 2025: Letter of Intent (LOI) deadline (5 pm ET) - January 13, 2026: Full application deadline (5 pm ET) --- ## Funding Amount - Maximum direct costs per project: $5 million - Maximum project duration: up to 5 years Funding is intended to support substantial, multi-year CER projects that can significantly advance the evidence base for rare diseases. --- ## Eligibility - Open to health researchers, scientists, healthcare professionals, research directors, academic institutions, and other qualified organizations. - Projects must focus on rare diseases and employ comparative clinical effectiveness research methodologies. - Strong emphasis on patient and stakeholder engagement throughout the research lifecycle. - Applicants are encouraged to review specific eligibility and responsiveness criteria in the full funding announcement. --- ## Application Process - Submit a Letter of Intent (LOI) by September 23, 2025, at 5 pm ET. - Applicants will be notified of LOI status by October 21, 2025. - Invited applicants must submit a full application by January 13, 2026, at 5 pm ET. - Review the [applicant town hall presentation slides](https://www.pcori.org/sites/default/files/PCORI-Cycle-3-2025-Rare-Disease-Applicant-Town-Hall-Presentation-Slides-081925.pdf) for detailed guidance. - Direct inquiries or requests for discussion to [pfa@pcori.org](mailto:pfa@pcori.org). --- ## Additional Information - Projects must demonstrate meaningful engagement with patients and stakeholders. - Proposals should address significant evidence gaps in rare diseases and be designed to produce actionable findings for patients and healthcare decision-makers. - For further details on requirements, merit review, and templates, visit the program's [official page](https://www.pcori.org/events/2025/cycle-3-2025-addressing-rare-diseases-pfa-applicant-town-hall). --- ## External Links - [ALS Association research funding opportunities](https://www.als.org/research/researchers/research-funding-opportunities) - [PCORI Cycle 3 2025 Addressing Rare Diseases PFA](https://www.pcori.org/events/2025/cycle-3-2025-addressing-rare-diseases-pfa-applicant-town-hall) - [Applicant Town Hall Presentation Slides (PDF)](https://www.pcori.org/sites/default/files/PCORI-Cycle-3-2025-Rare-Disease-Applicant-Town-Hall-Presentation-Slides-081925.pdf) --- ## Contact Information | Contact | Email | Phone | Web Contact Form | |-----------------------------|------------------------------|-------------------|---------------------------------------------------| | ALS Association | alsinfo@als.org | +1 800-782-4747 | [Contact ALSA](https://www.als.org/contact-us) | | PCORI (program inquiries) | pfa@pcori.org | Not listed | [PCORI Contact](https://www.pcori.org/about/contact-us) |

Cycle 3 2025 Addressing Rare Diseases PFA - ALS Association

Sign in to see full grant listing